Strategic intent : This investment highlights OneSources plan to establish a strong early foothold in the growing weight-loss generics segment
By examining the latest research findings and clinical insights, we aim to provide clinicians, researchers, and patients alike with a deeper understanding of this evolving therapeutic landscape
Available in a pen or vial, tirzepatide is injected subcutaneously (under the skin) into the abdomen, thigh, or upper arm
The Source: The information for this story was provided by the National Institutes of Health and the study titled: A brain reward circuit inhibited by next-generation weight-loss drugs in mice, published May 6, 2026 in Nature
170 WuY.SongJ.WangY.WangX.CulmseeC.ZhuC
If you are ready to explore whether it fits your situation, schedule a visit